Organisation paid for research Program year 2025 Source: CMS Open Payments

Dermresearch P.A.

Neither a doctor nor a teaching hospital

Research payments

$237,982

82 payments

Through program year 2025, Dermresearch P.A. is reported as receiving $237,982 in research payments, across 82 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$14,124	2
2024	Research	$71,543	48
2023	Research	$97,945	25
2022	Research	$54,371	7

Breakdown

Who paid Research payments · program years 2022–2025

Arcutis Biotherapeutics, Inc. $165,568 69 payments
Almirall LLC $72,414 13 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata $89,656 47 payments
M14867-32 $72,414 13 payments
A Phase 3, 8-Week, Parallel Group, Double blind, Vehicle-controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis (STRATUM) $27,447 3 payments
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis $15,334 6 payments
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR) $15,194 4 payments
A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis $11,689 3 payments
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis $4,261 4 payments
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis $1,987 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.